The conclusions of the meta-analysis by Kumar et al.
( 1 ) comparing single vs tandem transplantation in myeloma are compromised by serious errors and the retraction of a key study ( 2 ) included in the analysis.
The main conclusion of the metaanalysis is that tandem transplantation has no benefi cial effect on overall survival (OS) or event-free survival (EFS) in myeloma. All except one of the studies included in the meta-analysis showed comparable outcomes with the two approaches or some advantage for tandem transplantation. In contrast, a study from Abdelkefi et al. ( 2 ) showed dramatic benefi t of single transplantation over tandem.
When this study ( 2 ) was excluded from the meta-analysis to eliminate heterogeneity, EFS was statistically signifi cantly better with tandem transplantation ( 1 ). The benefi cial effect of tandem transplantation on OS also increased (improvement in the hazard ratio from 0.94 to 0.89) but did not reach the level of statistical signifi cance ( 1 ). The authors dismissed the importance of EFS as an endpoint reasoning that the definition of EFS "may be entirely due to outcomes that are not important to patients" ( 1 ). However, they did not point out the fact that the availability of effective salvage therapy in myeloma has made it diffi cult to show differences in OS. Although transplantation is not equivalent to a novel drug, the Food and Drug Administration does accept improvement in EFS as a valid endpoint for approval of novel drugs in myeloma.
The biologically implausible fi ndings of the study by Abdelkefi et al. ( 2 ) that contradicted previous fi ndings have been pointed out ( 3 ) . A careful review of the multiple online versions of the article (4, unpublished observations) and correspondence with the authors of the article and the editorial staff of Blood (unpublished data) uncovered inconsistencies and inaccuracies that cast doubt on the integrity of the study and resulted in retraction of the two articles describing the study ( 2 , 5 ). Retraction of this study alters the fi ndings of the metaanalysis of Kumar et al. and invalidates the summary results and conclusions contained in the abstract.
In addition, there are serious errors involving data extraction by the authors from four of the six trials ( 2 , 6 -8 ), which call into question the validity of the analysis. These errors have been summarized in Table 1 . It is not possible to assess the accuracy of the data estimated from the remaining two trials, which are unpublished. Indeed, the response data in the meta-analysis ( 1 ), shown in fi gure 3 of the article, bear no resemblance whatsoever to the actual response rates in the published studies.
Although the authors make much of the statistically signifi cant increase in treatment-related mortality with tandem transplantation, when the retracted study by Abdelkefi et al. is excluded and the denominator of patients in the single transplantation arm of the study by Sonneveld et al. ( 8 ) is corrected to 148 from 158 ( Table 1 ) , the risk ratio for treatment-related mortality becomes 1.60 (95% confi dence interval = 0.98 to 2.62) and its statistical signifi cance becomes borderline ( P = .059).
There are errors suggesting a misunderstanding of different types of failure events and their interrelationship. For example, figure 2 in the meta-analysis shows the number of events in both arms of the study by Abdelkefi et al. to be higher for OS than for EFS -which is biologically impossible.
The authors also did not discuss the fact that the Fermand study ( 9 ) included randomization to CD34-selected vs unmanipulated stem cell transplantation. After fi nding that CD34 selection increased infectious complications and bearing in mind that the use of unmanipulated cells is the standard of care now, Fermand analyzed the outcome of single vs tandem transplantation in the subgroup of patients receiving unmanipulated grafts and found jnci.oxfordjournals.org
OS better with tandem transplantation ( P = .04). Median EFS was longer with tandem transplantation as well (36 vs 31 months) but was not statistically signifi cant ( P = .11).
Notwithstanding the fact that the best long-term survival data in myeloma have been seen in studies that have had tandem transplantation as their key component ( 10 , 11 ) , the question of single vs tandem autotransplantation could still be considered open in some patient subpopulations. However, this meta-analysis is fl awed and should not infl uence important treatment decisions, which can compromise patient welfare. Indeed, over a period of a month The corrected TRM figures reduce the magnitude of the difference seen between the two arms, in favor of tandem transplantation.
